Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan

BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.

Abstract

Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.

Keywords: Lung cancer (oncology); Therapeutic indications.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms*
  • Camptothecin
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Female
  • Humans
  • Immunoconjugates*
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / therapeutic use

Substances

  • trastuzumab deruxtecan
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab
  • Camptothecin
  • Receptor, ErbB-2
  • Immunoconjugates